Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal
expansions of differentiated somatotroph cells and are usually sporadic. They are almost …

Pituitary adenomas are one of the most frequent intracranial tumors and occur with a
prevalence of approximately 1: 1000 in the developed world. Pituitary adenomas have a …

Abstract Purpose The 14th Acromegaly Consensus Conference was convened to consider
biochemical criteria for acromegaly diagnosis and evaluation of therapeutic efficacy …

Acromegaly is typically caused by a growth hormone–secreting pituitary adenoma, driving
excess secretion of insulin-like growth factor 1. Acromegaly may result in a variety of …

Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and
lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical …

X-linked acrogigantism (X-LAG) is a new syndrome of pituitary gigantism, caused by
microduplications on chromosome Xq26. 3, encompassing the gene GPR101, which is …

Aim To gather data regarding factors predicting responsiveness to pasireotide in
acromegaly. Patients and methods SSTR2a, SSTR3, SSTR5, AIP, Ki-67 and the adenoma …

First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical
treatment of acromegaly, however the percentage of patients controlled with these drugs …

Recently, a number of novel genetic alterations have been identified that predispose
individuals to pituitary adenomas. Clinically relevant pituitary adenomas are relatively …

Acromegaly is a chronic disease with increased morbidity and mortality, where usually
multiple treatment modalities are used. The somatostatin analogs (SSAs) are the mainstay of …